BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

551 related articles for article (PubMed ID: 22133722)

  • 21. Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort study.
    Zivanovic Bujak A; Weng CF; Silva MJ; Yeung M; Lo L; Ftouni S; Litchfield C; Ko YA; Kuykhoven K; Van Geelen C; Chandrashekar S; Dawson MA; Loi S; Wong SQ; Dawson SJ
    PLoS Med; 2020 Oct; 17(10):e1003363. PubMed ID: 33001984
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genome and transcriptome sequencing in prospective metastatic triple-negative breast cancer uncovers therapeutic vulnerabilities.
    Craig DW; O'Shaughnessy JA; Kiefer JA; Aldrich J; Sinari S; Moses TM; Wong S; Dinh J; Christoforides A; Blum JL; Aitelli CL; Osborne CR; Izatt T; Kurdoglu A; Baker A; Koeman J; Barbacioru C; Sakarya O; De La Vega FM; Siddiqui A; Hoang L; Billings PR; Salhia B; Tolcher AW; Trent JM; Mousses S; Von Hoff D; Carpten JD
    Mol Cancer Ther; 2013 Jan; 12(1):104-16. PubMed ID: 23171949
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of a Center for Personalized Cancer Care at a Regional Cancer Center: Feasibility Trial of an Institutional Tumor Sequencing Advisory Board.
    Lane BR; Bissonnette J; Waldherr T; Ritz-Holland D; Chesla D; Cottingham SL; Alberta S; Liu C; Thompson AB; Graveel C; MacKeigan JP; Noyes SL; Smith J; Lakhani N; Steensma MR;
    J Mol Diagn; 2015 Nov; 17(6):695-704. PubMed ID: 26331835
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Personalized genomic analyses for cancer mutation discovery and interpretation.
    Jones S; Anagnostou V; Lytle K; Parpart-Li S; Nesselbush M; Riley DR; Shukla M; Chesnick B; Kadan M; Papp E; Galens KG; Murphy D; Zhang T; Kann L; Sausen M; Angiuoli SV; Diaz LA; Velculescu VE
    Sci Transl Med; 2015 Apr; 7(283):283ra53. PubMed ID: 25877891
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-throughput detection of clinically relevant mutations in archived tumor samples by multiplexed PCR and next-generation sequencing.
    Bourgon R; Lu S; Yan Y; Lackner MR; Wang W; Weigman V; Wang D; Guan Y; Ryner L; Koeppen H; Patel R; Hampton GM; Amler LC; Wang Y
    Clin Cancer Res; 2014 Apr; 20(8):2080-91. PubMed ID: 24573554
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evolving landscape of tumor molecular profiling for personalized cancer therapy: a comprehensive review.
    Syn NL; Yong WP; Goh BC; Lee SC
    Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):911-22. PubMed ID: 27249175
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Testing personalized medicine: patient and physician expectations of next-generation genomic sequencing in late-stage cancer care.
    Miller FA; Hayeems RZ; Bytautas JP; Bedard PL; Ernst S; Hirte H; Hotte S; Oza A; Razak A; Welch S; Winquist E; Dancey J; Siu LL
    Eur J Hum Genet; 2014 Mar; 22(3):391-5. PubMed ID: 23860039
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Landscape of RAS Variations in 17,993 Pan-cancer Patients Identified by Next-generation Sequencing.
    Zhou S; Zhang D; Li J; Zhao J; Wang G; Zhang Y; Bai Y; Chen D; Wu H
    Pathol Oncol Res; 2020 Oct; 26(4):2835-2837. PubMed ID: 32602003
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Pilot Study of Clinical Targeted Next Generation Sequencing for Prostate Cancer: Consequences for Treatment and Genetic Counseling.
    Cheng HH; Klemfuss N; Montgomery B; Higano CS; Schweizer MT; Mostaghel EA; McFerrin LG; Yu EY; Nelson PS; Pritchard CC
    Prostate; 2016 Oct; 76(14):1303-11. PubMed ID: 27324988
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assigning clinical meaning to somatic and germ-line whole-exome sequencing data in a prospective cancer precision medicine study.
    Ghazani AA; Oliver NM; St Pierre JP; Garofalo A; Rainville IR; Hiller E; Treacy DJ; Rojas-Rudilla V; Wood S; Bair E; Parello M; Huang F; Giannakis M; Wilson FH; Stover EH; Corsello SM; Nguyen T; Rana HQ; Church AJ; Lowenstein C; Cibulskis C; Amin-Mansour A; Heng J; Brais L; Santos A; Bauer P; Waldron A; Lo P; Gorman M; Lydon CA; Welch M; McNamara P; Gabriel S; Sholl LM; Lindeman NI; Garber JE; Joffe S; Van Allen EM; Gray SW; Ja Nne PA; Garraway LA; Wagle N
    Genet Med; 2017 Jul; 19(7):787-795. PubMed ID: 28125075
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Whole-genome and transcriptome analysis enhances precision cancer treatment options.
    Pleasance E; Bohm A; Williamson LM; Nelson JMT; Shen Y; Bonakdar M; Titmuss E; Csizmok V; Wee K; Hosseinzadeh S; Grisdale CJ; Reisle C; Taylor GA; Lewis E; Jones MR; Bleile D; Sadeghi S; Zhang W; Davies A; Pellegrini B; Wong T; Bowlby R; Chan SK; Mungall KL; Chuah E; Mungall AJ; Moore RA; Zhao Y; Deol B; Fisic A; Fok A; Regier DA; Weymann D; Schaeffer DF; Young S; Yip S; Schrader K; Levasseur N; Taylor SK; Feng X; Tinker A; Savage KJ; Chia S; Gelmon K; Sun S; Lim H; Renouf DJ; Jones SJM; Marra MA; Laskin J
    Ann Oncol; 2022 Sep; 33(9):939-949. PubMed ID: 35691590
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical sequencing using a next-generation sequencing-based multiplex gene assay in patients with advanced solid tumors.
    Kou T; Kanai M; Yamamoto Y; Kamada M; Nakatsui M; Sakuma T; Mochizuki H; Hiroshima A; Sugiyama A; Nakamura E; Miyake H; Minamiguchi S; Takaori K; Matsumoto S; Haga H; Seno H; Kosugi S; Okuno Y; Muto M
    Cancer Sci; 2017 Jul; 108(7):1440-1446. PubMed ID: 28440963
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity.
    Beltran H; Yelensky R; Frampton GM; Park K; Downing SR; MacDonald TY; Jarosz M; Lipson D; Tagawa ST; Nanus DM; Stephens PJ; Mosquera JM; Cronin MT; Rubin MA
    Eur Urol; 2013 May; 63(5):920-6. PubMed ID: 22981675
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Next generation sequencing in cancer: opportunities and challenges for precision cancer medicine.
    Paolillo C; Londin E; Fortina P
    Scand J Clin Lab Invest Suppl; 2016; 245():S84-91. PubMed ID: 27542004
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeted NGS, array-CGH, and patient-derived tumor xenografts for precision medicine in advanced breast cancer: a single-center prospective study.
    Gonçalves A; Bertucci F; Guille A; Garnier S; Adelaide J; Carbuccia N; Cabaud O; Finetti P; Brunelle S; Piana G; Tomassin-Piana J; Paciencia M; Lambaudie E; Popovici C; Sabatier R; Tarpin C; Provansal M; Extra JM; Eisinger F; Sobol H; Viens P; Lopez M; Ginestier C; Charafe-Jauffret E; Chaffanet M; Birnbaum D
    Oncotarget; 2016 Nov; 7(48):79428-79441. PubMed ID: 27765906
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door.
    Verlingue L; Hollebecque A; Lacroix L; Postel-Vinay S; Varga A; El Dakdouki Y; Baldini C; Balheda R; Gazzah A; Michot JM; Marabelle A; Mir O; Arnedos M; Rouleau E; Solary E; De Baere T; Angevin E; Armand JP; Michiels S; André F; Deutsch E; Scoazec JY; Soria JC; Massard C
    Eur J Cancer; 2018 Mar; 92():1-10. PubMed ID: 29413684
    [TBL] [Abstract][Full Text] [Related]  

  • 37. On the Road to Precision Cancer Medicine: Analysis of Genomic Biomarker Actionability in 439 Patients.
    Schwaederle M; Daniels GA; Piccioni DE; Fanta PT; Schwab RB; Shimabukuro KA; Parker BA; Kurzrock R
    Mol Cancer Ther; 2015 Jun; 14(6):1488-94. PubMed ID: 25852059
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of a Collaboration Between a Health Plan, Oncology Practice, and Comprehensive Genomic Profiling Company from the Payer Perspective.
    Reitsma M; Fox J; Borre PV; Cavanaugh M; Chudnovsky Y; Erlich RL; Gribbin TE; Anhorn R
    J Manag Care Spec Pharm; 2019 May; 25(5):601-611. PubMed ID: 30632889
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bone biopsy protocol for advanced prostate cancer in the era of precision medicine.
    Sailer V; Schiffman MH; Kossai M; Cyrta J; Beg S; Sullivan B; Pua BB; Lee KS; Talenfeld AD; Nanus DM; Tagawa ST; Robinson BD; Rao RA; Pauli C; Bareja R; Beltran LS; Sigaras A; Eng KW; Elemento O; Sboner A; Rubin MA; Beltran H; Mosquera JM
    Cancer; 2018 Mar; 124(5):1008-1015. PubMed ID: 29266381
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology.
    Cheng DT; Mitchell TN; Zehir A; Shah RH; Benayed R; Syed A; Chandramohan R; Liu ZY; Won HH; Scott SN; Brannon AR; O'Reilly C; Sadowska J; Casanova J; Yannes A; Hechtman JF; Yao J; Song W; Ross DS; Oultache A; Dogan S; Borsu L; Hameed M; Nafa K; Arcila ME; Ladanyi M; Berger MF
    J Mol Diagn; 2015 May; 17(3):251-64. PubMed ID: 25801821
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.